[go: up one dir, main page]

ES2124905T3 - Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad. - Google Patents

Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.

Info

Publication number
ES2124905T3
ES2124905T3 ES94924819T ES94924819T ES2124905T3 ES 2124905 T3 ES2124905 T3 ES 2124905T3 ES 94924819 T ES94924819 T ES 94924819T ES 94924819 T ES94924819 T ES 94924819T ES 2124905 T3 ES2124905 T3 ES 2124905T3
Authority
ES
Spain
Prior art keywords
treatment
anxiety disorders
pct
antiglucocorticoid steroids
antiglucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94924819T
Other languages
English (en)
Inventor
Bernardus Wynand Machi Peeters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akzo Nobel NV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of ES2124905T3 publication Critical patent/ES2124905T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE ESTEROIDES ANTIGLUCOCORTICOIDES PARA LA MANUFACTURA DE UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA ANSIEDAD.
ES94924819T 1993-08-04 1994-07-28 Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad. Expired - Lifetime ES2124905T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93202304 1993-08-04
EP94924819A EP0712311B1 (en) 1993-08-04 1994-07-28 Antiglucocorticoid steroids for the treatment of anxiety disorders
PCT/EP1994/002513 WO1995004536A1 (en) 1993-08-04 1994-07-28 Antiglucocorticoid steroids for the treatment of anxiety disorders

Publications (1)

Publication Number Publication Date
ES2124905T3 true ES2124905T3 (es) 1999-02-16

Family

ID=8214027

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94924819T Expired - Lifetime ES2124905T3 (es) 1993-08-04 1994-07-28 Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.

Country Status (11)

Country Link
US (1) US5741787A (es)
EP (1) EP0712311B1 (es)
JP (1) JP3828926B2 (es)
AT (1) ATE171873T1 (es)
AU (1) AU687088B2 (es)
CA (1) CA2166332C (es)
DE (1) DE69413829T2 (es)
DK (1) DK0712311T3 (es)
ES (1) ES2124905T3 (es)
NZ (1) NZ271363A (es)
WO (1) WO1995004536A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2106616T3 (es) * 1994-05-19 1997-11-01 Akzo Nobel Nv Derivados de 11,21-bisfenilo-19-nor-pregnanos.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL119649A (en) * 1995-11-30 2002-03-10 Akzo Nobel Nv Preparation of Cyclic Kills of History - 3 keto- (5) 10, (-9) 11 steroidadians
EP0780397B1 (de) * 1995-12-22 1998-06-10 Jenapharm GmbH & Co. KG Neue 17alpha-Cyanomethylestra-4,9-dien-derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
JP4260886B2 (ja) * 1996-05-01 2009-04-30 アメリカ合衆国 新規の抗プロゲステロンとしての２１―置換プロゲステロン誘導体
FR2757400B1 (fr) * 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
EP1079859B1 (en) 1998-05-22 2010-07-14 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
PT1100483E (pt) * 1998-07-30 2005-02-28 Abbott Lab Agentes anti-inflamatorios selectivos para glicocorticoide
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US7250408B2 (en) 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
WO2004078709A2 (en) * 2003-02-28 2004-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHOD FOR PREPARING 17 α-ACETOXY-11β-(4-N,N-DIMETHYLAMINOPHENYL)-19-NORPREGNA-4,9-DIENE-3,20-DIONE, INTERMEDIATES THEREOF, AND METHODS FOR THE PREPARATION OF SUCH INTERMEDIATES
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
CA2789262C (en) 2005-04-28 2016-10-04 Proteus Digital Health, Inc. Pharma-informatics system
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
AU2016379417B2 (en) 2015-12-23 2020-09-24 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
DK3523315T3 (da) 2016-10-07 2021-05-03 Oric Pharmaceuticals Inc Inhibitor af glucocorticoidreceptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series

Also Published As

Publication number Publication date
AU687088B2 (en) 1998-02-19
DE69413829T2 (de) 1999-04-15
EP0712311A1 (en) 1996-05-22
JPH09501172A (ja) 1997-02-04
WO1995004536A1 (en) 1995-02-16
CA2166332C (en) 2005-05-10
EP0712311B1 (en) 1998-10-07
NZ271363A (en) 1999-06-29
JP3828926B2 (ja) 2006-10-04
DE69413829D1 (de) 1998-11-12
ATE171873T1 (de) 1998-10-15
AU7496894A (en) 1995-02-28
DK0712311T3 (da) 1999-06-21
US5741787A (en) 1998-04-21
CA2166332A1 (en) 1995-02-16

Similar Documents

Publication Publication Date Title
ES2124905T3 (es) Esteroides antiglucocorticoides destinados al tratamiento de trastornos de ansiedad.
ATE255589T1 (de) Kristallin form i von clarithromycin
HUT72436A (en) Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases
CA2304770A1 (en) A use of steroidal saponins for the prophylaxis or treatment of dementia, and novel steroidal saponin compounds
DE69432752D1 (de) Zusammensetzung zur substitutionstherapie, die mindestens ein progestogen und mindestens ein oestrogen enthält
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60229530D1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
DE69626818D1 (de) Zusammensetzung welche einen darmbakterienstamm und glutamin enthält
GB0111186D0 (en) Novel compounds
AP9801269A0 (en) Prostaglandin agonists.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
DK0989973T3 (da) Chalconer med antiproliferativ aktivitet
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
AU4179399A (en) Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
BG103060A (en) 19-nor-holan steroids as neurochemical initiators of the change of the operation of the hypothalamus in human organism
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
DE60209248D1 (de) Verwendung von (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propinyl)-estra-4,9-dien-3-on zur behandlung von schweren depressionen
ZA944317B (en) New phosphonosuccinic acid derivatives processes for the preparation thereof and pharmaceutical compositions containing them
AU2796695A (en) Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
HU9603631D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 712311

Country of ref document: ES